Amino acid-derived ionizable lipids enable inhaled base editing for therapeutic gene correction in the lung
Source abstract
Abstract
CRISPR-based gene editing holds promise for treating genetic diseases, yet its application to lung disorders has been hindered by the challenges of pulmonary delivery. Inspired by the modularity and biocompatibility of amino acid-derived chemistries, we report the combinatorial synthesis of 960 ionizable lipids incorporating chemically diverse backbones from both proteinogenic and non-proteinogenic α-amino acids. Through high-throughput screening and structure-function analysis, we identify CHCha-10, a cyclohexyl amino acid-derived lipid that forms biodegradable nanoparticles capable of efficiently delivering mRNA-based gene editors to lung epithelial cells. Following intratracheal administration, CHCha-10 nanoparticles exhibit enhanced mucus penetration and epithelial-specific transfection in both mice and ferrets. Here, as a functional application, we demonstrate in vivo base editing in the lung via inhalation. Delivery of adenine base editor mRNA and guide RNA targeting the CFTR G542X mutation restores CFTR expression and chloride channel function in G542X human airway epithelial cells, mouse-derived intestinal organoids and the lungs of cystic fibrosis mice. This work establishes a chemically modular design framework for ionizable lipids and a translatable platform for RNA-based pulmonary gene correction.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · CRISPR and Genetic Engineering · RNA and protein synthesis mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (80)
Show source-provided references
1. Cullot, G. et al. CRISPR–Cas9 genome editing induces megabase-scale chromosomal truncations. Nat. Commun. 10, 1136 (2019).10.1038/s41467-019-09006-2 ↗
2. Porto, E. M., Komor, A. C., Slaymaker, I. M. & Yeo, G. W. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug Discov. 19, 839–859 (2020).10.1038/s41573-020-0084-6 ↗
3. Gaudelli, N. M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).10.1038/nature24644 ↗
4. Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235–2243 (2025).10.1056/NEJMoa2504747 ↗
5. Davis, J. R. et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat. Biomed. Eng. 6, 1272–1283 (2022).10.1038/s41551-022-00911-4 ↗
6. Zhang, H. et al. Adenine base editing in vivo with a single adeno-associated virus vector. GEN Biotechnol. 1, 285–299 (2022).10.1089/genbio.2022.0015 ↗
7. Kim, D. Y. et al. Hypercompact adenine base editors based on transposase B guided by engineered RNA. Nat. Chem. Biol. 18, 1005–1013 (2022).10.1038/s41589-022-01077-5 ↗
8. Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97–110 (2020).10.1038/s41551-019-0501-5 ↗
9. Xu, L. et al. Efficient precise in vivo base editing in adult dystrophic mice. Nat. Commun. 12, 3719 (2021).10.1038/s41467-021-23996-y ↗
10. Koblan, L. W. et al. In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice. Nature 589, 608–614 (2021).10.1038/s41586-020-03086-7 ↗
11. Choi, E. H. et al. In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration. Nat. Commun. 13, 1830 (2022).10.1038/s41467-022-29490-3 ↗
12. Cui, C. et al. A base editor for the long-term restoration of auditory function in mice with recessive profound deafness. Nat. Biomed. Eng. 9, 40–56 (2024).10.1038/s41551-024-01235-1 ↗
13. Guo, C., Ma, X., Gao, F. & Guo, Y. Off-target effects in CRISPR/Cas9 gene editing. Front. Bioeng. Biotechnol. 11, 1143157 (2023).10.3389/fbioe.2023.1143157 ↗
14. Brommel, C. M., Cooney, A. L. & Sinn, P. L. Adeno-associated virus-based gene therapy for lifelong correction of genetic disease. Hum. Gene Ther. 31, 985–995 (2020).10.1089/hum.2020.138 ↗
15. Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23–36 (2013).10.1182/blood-2013-01-306647 ↗
16. Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).10.1038/s41586-021-03534-y ↗
17. Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).10.1038/s41587-021-00933-4 ↗
18. Qiu, M. et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc. Natl Acad. Sci. USA 118, e2020401118 (2021).10.1073/pnas.2020401118 ↗
19. Song, C. Q. et al. Adenine base editing in an adult mouse model of tyrosinaemia. Nat. Biomed. Eng. 4, 125–130 (2020).10.1038/s41551-019-0357-8 ↗
20. Jiang, T. et al. Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. Nat. Commun. 11, 1979 (2020).10.1038/s41467-020-15892-8 ↗
21. Turuvekere Vittala Murthy, N., Vlasova, K., Renner, J., Jozic, A. & Sahay, G. A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines. Adv. Drug Deliv. Rev. 209, 115305 (2024).10.1016/j.addr.2024.115305 ↗
22. Patel, M. N. et al. Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids. Nat. Biotechnol. 44, 79–89 (2025).10.1038/s41587-025-02556-5 ↗
23. Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol. 43, 1790–1799 (2024).10.1038/s41587-024-02490-y ↗
24. Zhao, S. et al. Acid-degradable lipid nanoparticles enhance the delivery of mRNA. Nat. Nanotechnol. 19, 1702–1711 (2024).10.1038/s41565-024-01765-4 ↗
25. Fenton, O. S. et al. Customizable lipid nanoparticle materials for the delivery of siRNAs and mRNAs. Angew. Chem. Int. Ed. Engl. 57, 13582–13586 (2018).10.1002/anie.201809056 ↗
26. Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).10.1038/s41587-019-0247-3 ↗
27. Chen, J. et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proc. Natl Acad. Sci. USA 120, e2309472120 (2023).10.1073/pnas.2309472120 ↗
28. Xu, S. et al. Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy. Adv. Mater. 36, e2400307 (2024).10.1002/adma.202400307 ↗
29. Renner, J. et al. Synthesis of ionizable lipids for gene delivery to the lung using an ugi four component reaction. J. Am. Chem. Soc. 147, 17459–17467 (2025).10.1021/jacs.5c04123 ↗
30. Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).10.1038/s41467-024-50619-z ↗
31. Cornebise, M. et al. Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA. Adv. Funct. Mater. 32, 2106727 (2022).10.1002/adfm.202106727 ↗
32. Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955–3960 (2014).10.1073/pnas.1322937111 ↗
33. Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300–7306 (2015).10.1021/acs.nanolett.5b02497 ↗
34. Fenton, O. S. et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 29, 1606944 (2017).10.1002/adma.201606944 ↗
35. Neve, R. L., Carrillo, B. D. & Phelan, V. V. Impact of artificial sputum medium formulation on Pseudomonas aeruginosa secondary metabolite production. J. Bacteriol. 203, e0025021 (2021).10.1128/JB.00250-21 ↗
36. Tang, X. X. et al. Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J. Clin. Invest. 126, 879–891 (2016).10.1172/JCI83922 ↗
37. Guo, Y. et al. Mucus penetration of surface-engineered nanoparticles in various pH microenvironments. ACS Nano 17, 2813–2828 (2023).10.1021/acsnano.2c11147 ↗
38. Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533–542 (2022).10.1021/acs.nanolett.1c02503 ↗
39. Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410–1415 (2023).10.1038/s41587-023-01679-x ↗
40. Kauffman, K. J. et al. Rapid, single-cell analysis and discovery of vectored mRNA transfection in vivo with a loxP-flanked tdTomato reporter mouse. Mol. Ther. Nucleic Acids 10, 55–63 (2018).10.1016/j.omtn.2017.11.005 ↗
41. Zhang, W. et al. Lipid carriers for mRNA delivery. Acta Pharm. Sin. B 13, 4105–4126 (2023).10.1016/j.apsb.2022.11.026 ↗
42. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).10.1038/s41467-020-14527-2 ↗
43. Liu, S. et al. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination. Nat. Commun. 15, 9471 (2024).10.1038/s41467-024-53914-x ↗
44. Ha, J. G. & Cho, H. J. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int. J. Mol. Sci. 24, 14229 (2023).10.3390/ijms241814229 ↗
45. Tummler, B. Progress in understanding the molecular pathology and microbiology of cystic fibrosis. Lancet Respir. Med. 8, 8–10 (2020).10.1016/S2213-2600(19)30333-9 ↗
46. Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196–1202 (2024).10.1126/science.adk9428 ↗
47. Shah, V. S. & Rajagopal, J. Cystic fibrosis: ‘ionocyte modulators’?. Am. J. Respir. Cell Mol. Biol. 69, 250–252 (2023).10.1165/rcmb.2023-0169ED ↗
48. Hewitt, R. J. & Lloyd, C. M. Regulation of immune responses by the airway epithelial cell landscape. Nat. Rev. Immunol. 21, 347–362 (2021).10.1038/s41577-020-00477-9 ↗
49. Rosen, B. H. et al. Animal and model systems for studying cystic fibrosis. J. Cyst Fibros. 17, S28–S34 (2018).10.1016/j.jcf.2017.09.001 ↗
50. Sun, X. et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J. Clin. Invest. 120, 3149–3160 (2010).10.1172/JCI43052 ↗
51. Yu, M. et al. Highly efficient transgenesis in ferrets using CRISPR/Cas9-mediated homology-independent insertion at the ROSA26 locus. Sci. Rep. 9, 1971 (2019).10.1038/s41598-018-37192-4 ↗
52. Luo, M. et al. Genome editing in ferret airway epithelia mediated by CRISPR/nucleases delivered with amphiphilic shuttle peptides. Hum. Gene Ther. 34, 705–718 (2023).10.1089/hum.2023.016 ↗
53. Carraro, G. & Stripp, B. R. Roles for myoepithelial cells in the formation and maintenance of submucosal glands. Am. J. Respir. Cell Mol. Biol. 56, 685–686 (2017).10.1165/rcmb.2017-0044ED ↗
54. Fiumara, M. et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat. Biotechnol. 42, 877–891 (2024).10.1038/s41587-023-01915-4 ↗
55. Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR–Cas9 variants. Science 368, 290–296 (2020).10.1126/science.aba8853 ↗
56. Lueck, J. D. et al. Engineered transfer RNAs for suppression of premature termination codons. Nat. Commun. 10, 822 (2019).10.1038/s41467-019-08329-4 ↗
57. Albers, S. et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo. Nature 618, 842–848 (2023).10.1038/s41586-023-06133-1 ↗
58. Alves, C. R. R. et al. Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. Nat. Biomed. Eng. 8, 118–131 (2024).10.1038/s41551-023-01132-z ↗
59. Cao, X. et al. Engineering of near-PAMless adenine base editor with enhanced editing activity and reduced off-target. Mol. Ther. Nucleic Acids 28, 732–742 (2022).10.1016/j.omtn.2022.04.032 ↗
60. Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892–900 (2020).10.1038/s41587-020-0491-6 ↗
61. Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z. & Blakney, A. K. Optimization of lipid nanoparticles for saRNA expression and cellular activation using a design-of-experiment approach. Mol. Pharm. 19, 1892–1905 (2022).10.1021/acs.molpharmaceut.2c00032 ↗
62. Wei, T. et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models. Nat. Commun. 14, 7322 (2023).10.1038/s41467-023-42948-2 ↗
63. Lahr, W. S., Sipe, C. J., Skeate, J. G., Webber, B. R. & Moriarity, B. S. CRISPR–Cas9 base editors and their current role in human therapeutics. Cytotherapy 25, 270–276 (2023).10.1016/j.jcyt.2022.11.013 ↗
64. Yu, S. Y. et al. A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid nanoparticle delivery of adenine base editors. Mol. Ther. 31, 1159–1166 (2023).10.1016/j.ymthe.2023.02.009 ↗
65. Molinski, S. V., Ahmadi, S., Hung, M. & Bear, C. E. Facilitating structure–function studies of CFTR modulator sites with efficiencies in mutagenesis and functional screening. J. Biomol. Screen. 20, 1204–1217 (2015).10.1177/1087057115605834 ↗
66. McHugh, D. R. et al. A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies. PLoS ONE 13, e0199573 (2018).10.1371/journal.pone.0199573 ↗
67. Kluesner, M. G. et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239–250 (2018).10.1089/crispr.2018.0014 ↗
68. Kluesner, M. G., Nedveck, D. A., Lahr, W. S., Garbe, J., Abrahante, J., Webber, B. & Moriarty, B. S. EditR: a method to quantify base editing via Sanger sequencing. The CRISPR Journal http://moriaritylab.shinyapps.io/editr_v10/ (2018).10.1089/crispr.2018.0014 ↗
69. Xu, Y. et al. LUMI-lab: a foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery. Cell https://doi.org/10.1016/j.cell.2026.01.012 (2026).10.1016/j.cell.2026.01.012 ↗
70. Liu, H. & Dömling, A. One-pot synthesis of highly functionalized seleno amino acid derivatives. Chem. Biol. Drug Des. 74, 302–308 (2009).10.1111/j.1747-0285.2009.00854.x ↗
71. Tao, Y. & Tao, Y. Ugi reaction of amino acids: from facile synthesis of polypeptoids to sequence-defined macromolecules. Macromol. Rapid Commun. 42, e2000515 (2021).10.1002/marc.202000515 ↗
72. Pérez-Labrada, K. et al. Combined Ugi-4CR/CuAAC approach to triazole-based neoglycolipids. Eur. J. Org. Chem. 2014, 3671–3683 (2014).10.1002/ejoc.201402117 ↗
73. Stewart, C. E., Torr, E. E., Mohd Jamili, N. H., Bosquillon, C. & Sayers, I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J. Allergy 2012, 943982 (2012).10.1155/2012/943982 ↗
74. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
75. Zhang, J., Fan, H., Levorse, D. A. & Crocker, L. S. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. Langmuir 27, 1907–1914 (2011).10.1021/la104590k ↗
76. Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).10.1038/s42003-021-02441-2 ↗
77. Pisu, D. & Russell, D. G. Protocol for multi-modal single-cell RNA sequencing on M. tuberculosis-infected mouse lungs. STAR Protoc. 4, 102102 (2023).10.1016/j.xpro.2023.102102 ↗
78. Kang, M. H. et al. A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency. Nat. Commun. 11, 3929 (2020).10.1038/s41467-020-17577-8 ↗
79. Wong, A. P. et al. Efficient generation of functional CFTR-expressing airway epithelial cells from human pluripotent stem cells. Nat. Protoc. 10, 363–381 (2015).10.1038/nprot.2015.021 ↗
80. Xu, Y., Li, G. & Li, B. Amino acid-derived ionizable lipids enable inhaled base editing for therapeutic gene correction in the lung. Zenodo https://doi.org/10.5281/zenodo.18613180 (2026).10.5281/zenodo.18613180 ↗